Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
Colorcon
McKinsey
AstraZeneca

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Brivanib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Brivanib?

Brivanib is an investigational drug.

There have been 23 clinical trials for Brivanib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Colorectal Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, Gynecologic Oncology Group, and National Cancer Institute (NCI).

Recent Clinical Trials for Brivanib
TitleSponsorPhase
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerHunan Cancer HospitalPhase 1
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCZai Lab (Shanghai) Co., Ltd.Phase 2
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)Bristol-Myers SquibbPhase 1

See all Brivanib clinical trials

Clinical Trial Summary for Brivanib

Top disease conditions for Brivanib
Top clinical trial sponsors for Brivanib

See all Brivanib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Express Scripts
Medtronic
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.